KYMR Share Price Performance
US$66.62
22.97 (52.62%)
14.1% undervalued intrinsic discount
US$77.59
Fair Value
Price US$66.62
AnalystConsensusTarget US$77.59
Fair ValueUS$77.59
Share Pricen/a
Kymera Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
KYMR Community Narratives
AN
Fair Value US$77.59 14.1% undervalued intrinsic discount
KYMR: Advancing Clinical Milestones Will Drive Meaningful Upside in Immunology Indications
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
KYMR: Advancing Clinical Milestones Will Drive Meaningful Upside in Immunology Indications
Key Takeaways Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings. Solid cash runway supports focused R&D investments, potentially boosting long-term growth without immediate financing pressures.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$77.59
14.1% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
-0.038% p.a.
Profit Margin
16.03%
Future PE
1.2kx
Price in 2028
US$95.06
Trending Discussion
Recently Updated Narratives
AN
KYMR: Upcoming Atopic Dermatitis Data Will Unlock Major Upside Potential
Fair Value: US$77.59 14.1% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kymera Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -4.10
- -596.36%
- -674.80%
- 0%
About KYMR
- Founded
- 2015
- Employees
- 225
- CEO
- WebsiteView website
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
